Literature DB >> 8395511

The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.

M Jannatipour1, Y X Liu, J L Nitiss.   

Abstract

We have characterized a temperature-sensitive mutant in the yeast TOP2 gene that shows resistance to the anti-topoisomerase II agents amsacrine and etoposide. Cells carrying the top2-5 mutant have a minimum lethal concentration of amsacrine of greater than 100 micrograms/ml, compared to 10 micrograms/ml in isogenic wild-type cells, and a minimum lethal concentration of greater than 100 micrograms/ml etoposide, compared with 50 micrograms/ml for cells carrying wild-type topoisomerase II. We have cloned the top2-5 allele into a yeast vector that allows high level overexpression of the protein. As expected, the purified top2-5 activity is temperature-sensitive. The protein shows a 3-fold reduction of amsacrine-stabilized cleavage at the permissive temperature, confirming that the top2-5 protein is resistant to amsacrine in vitro. The protein also exhibits reduced cleavage in the presence of etoposide, with the largest effect at low concentrations of the drug. These results suggest that the top2-5 protein is altered in its sensitivity to anti-topoisomerase II agents. The relevant portion of the mutant allele has been sequenced, and several tightly clustered mutations have been identified. The location of the mutations identify a domain of the topoisomerase II protein that may be important in the interaction of the protein with anti-topoisomerase II anti-cancer drugs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395511

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast.

Authors:  Nicole Stantial; Anna Rogojina; Matthew Gilbertson; Yilun Sun; Hannah Miles; Samantha Shaltz; James Berger; Karin C Nitiss; Sue Jinks-Robertson; John L Nitiss
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-12       Impact factor: 11.205

2.  Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells.

Authors:  M Del Poeta; S F Chen; D Von Hoff; C C Dykstra; M C Wani; G Manikumar; J Heitman; M E Wall; J R Perfect
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

3.  Topoisomerase assays.

Authors:  John L Nitiss; Eroica Soans; Anna Rogojina; Aman Seth; Margarita Mishina
Journal:  Curr Protoc Pharmacol       Date:  2012-06

4.  Antifungal activity of eupolauridine and its action on DNA topoisomerases.

Authors:  Shabana I Khan; Alison C Nimrod; Mohammed Mehrpooya; John L Nitiss; Larry A Walker; Alice M Clark
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

5.  Analysis of functional domain organization in DNA topoisomerase II from humans and Saccharomyces cerevisiae.

Authors:  S Jensen; A H Andersen; E Kjeldsen; H Biersack; E H Olsen; T B Andersen; O Westergaard; B K Jakobsen
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

6.  Energy-dependent mitochondrial mutagenicity of antibacterial ofloxacin and its recombinogenic activity in yeast.

Authors:  M Obernauerová; J Subík
Journal:  Curr Genet       Date:  1994-09       Impact factor: 3.886

7.  DNA repair functions that control sensitivity to topoisomerase-targeting drugs.

Authors:  Mobeen Malik; John L Nitiss
Journal:  Eukaryot Cell       Date:  2004-02

8.  Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.

Authors:  Anna T Rogojina; John L Nitiss
Journal:  J Biol Chem       Date:  2008-08-22       Impact factor: 5.157

Review 9.  Using yeast to study resistance to topoisomerase II-targeting drugs.

Authors:  J L Nitiss
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  An etoposide-induced block in vaccinia virus telomere resolution is dependent on the virus-encoded DNA ligase.

Authors:  A M DeLange; M S Carpenter; J Choy; V E Newsway
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.